Addressing the Unmet Need for a Comprehensive Lung Cancer Registry in Romania

A person with lung cancer can pass through months of care while leaving fragments of the same story in several places. A radiologist records a shadow on a scan. A pathology laboratory identifies malignant cells in a tissue sample. An oncology centre stores the treatment plan, while another hospital may eventually record the outcome. Each document can guide the clinician who sees it. Together they should tell Romania where cancers are found late, which patients struggle to reach specialist care and whether treatment is improving. In practice, those fragments rarely form a complete national picture.

The missing structure is a comprehensive cancer registry, a protected record of every diagnosed case in a defined population. Its value grows from continuity. A registry can follow the stage at which a tumour was found, the care a person received and how long that person survived. It can connect those details with age and area of residence while keeping identifying information under strict control. Thousands of individual journeys then become visible as a population pattern. A delay that looks like private misfortune in one file may emerge as a regional failure when the files are read together.

My four colleagues and I argued for such a system after the pandemic revealed lung cancer in an unexpected way. People with suspected COVID-19 often underwent chest imaging, including computed tomography, or CT. The scanner combines many X-ray views into a detailed image of the body. Clinicians looking for the signs of viral pneumonia sometimes found a suspicious mass instead. These chance discoveries did not amount to a screening programme, yet they exposed tumours that had produced no unmistakable symptom and might otherwise have remained hidden.

That matters because lung cancer often declares itself late. A cough can be attributed to smoking or a recent infection, while breathlessness develops gradually enough to seem ordinary. By the time the pattern becomes impossible to ignore, malignant cells may have moved beyond the lung. Doctors call this extent the cancer's stage, and stage shapes both the treatments available and the chance of long-term survival. An incidental scan offered some patients an earlier starting point. It also raised a question Romania's scattered records could not answer: how many others are still arriving after that opportunity has passed?

A registry would turn the question into measures that services can act upon. It could follow the time between a suspicious image and diagnostic confirmation, then record the wait before treatment. It could reveal whether people living far from major centres enter care later than residents of large cities. Changes could be tracked after a referral pathway or new scanning service was introduced. The purpose would extend beyond counting cases. It would connect the course of a disease with the health system through which every patient has to move.

Planning would become more precise as a result. Lung-cancer care depends on radiologists and pathology laboratories, cancer physicians and surgeons, specialist nurses and services that relieve pain or breathlessness. A national picture can show where demand is rising and where one missing link slows the entire pathway. Modern treatment may also depend on molecular markers inside tumour cells, since certain changes indicate that a targeted medicine is likely to work. Recording those tests would reveal whether advanced diagnosis is available across Romania or concentrated around a few institutions.

Prevention belongs in the same record. Tobacco remains the leading cause of lung cancer, although the disease also occurs among people who have never smoked. A registry can follow incidence, the number of new diagnoses during a period, alongside mortality, the number of deaths. If mortality falls while incidence remains similar, earlier detection or more effective treatment may be contributing. A stubborn rise in one region would prompt closer study of exposure, access and reporting. Without stable denominators across many years, apparent changes can be little more than noise.

Building that stability requires patient, largely invisible work. One person may appear in several hospital systems under slightly different details. Public and private providers may use incompatible terms. Some cancers are confirmed through tissue, while a frail patient might be treated on imaging and clinical judgement. Trained registry staff need rules for resolving contradictions and enough authority to pursue missing information. Software helps records travel, but interoperability also depends on people agreeing what each field means. A national database filled automatically with incomparable data would create confidence without knowledge.

Privacy has to be designed with the same care. The registry needs enough detail to connect records and avoid counting one patient twice. Access should remain limited, audited and governed by transparent rules. Researchers usually work with data from which direct identifiers have been removed, although de-identification reduces risk rather than erasing it. Patients deserve a clear account of what is collected, who may use it and how a research request is judged. A registry built for public benefit gains legitimacy when its stewardship is visible.

The case for screening shows why dependable evidence matters. Low-dose CT can find small abnormalities in people at elevated risk, often because of age and a substantial smoking history. Many of those abnormalities are harmless. Follow-up can cause anxiety and sometimes leads to invasive procedures. Romanian data would help determine whether a screening programme finds dangerous tumours earlier within the country's own referral system, whether invited groups can attend and whether harms remain proportionate to benefit. A policy that succeeds elsewhere still has to work through Romania's geography and workforce.

Quality would need to be measured continuously. Completeness asks whether the registry captures most eligible cancers. Validity asks whether the entries agree with clinical evidence, while timeliness concerns how quickly a diagnosis appears. Comparison with pathology records and hospital discharge data can uncover missing cases. Survival statistics need equal care. Earlier diagnosis can make survival from the date of diagnosis appear longer even when the date of death is unchanged, a distortion known as lead-time bias. Stage and patient characteristics must be considered before better figures are credited to better treatment.

The patient can remain visible inside all this measurement. Survival matters profoundly, yet people also care about pain, breathlessness and whether they can work or look after family. Patient-reported outcomes collect these experiences directly. Paired with clinical records, they can reveal whether longer life is accompanied by a bearable daily life and where supportive care is thin. Patients should help decide which outcomes the registry follows, especially when the technically easiest measure misses what illness feels like.

Public reporting would complete the route from record to reform. Maps and carefully explained comparisons can show where diagnosis remains late without exposing small communities or individuals. Internationally compatible definitions would let Romania learn from other countries, provided differences in population age and registration are taken seriously. The point is inquiry rather than a league table. A useful comparison identifies a plausible improvement, then asks whether it can survive in Romanian services.

A national registry would also widen the evidence available for research. Investigators could see whether a promising treatment reaches routine care outside a major centre or identify groups whose outcomes differ in ways that deserve closer study. Eligible patients could be approached about clinical trials through properly governed procedures, rather than being found only at hospitals with strong research networks. That broader view would make Romanian research more representative of the people the health system actually serves.

Data alone cannot shorten a referral. Each recurring gap needs a named institution with the authority and resources to respond, followed by a deadline the public can see. That is why permanent funding and governance matter after the excitement of launch has passed. A registry that disappears with a grant loses years of accumulated value. One that produces annual reports without changing decisions becomes an archive of preventable inequality.

A registry will never diagnose a tumour or sit beside a frightened patient. Its influence is quieter and broader. It gives a health system enough memory to recognise when the same delay is happening again, and enough evidence to stop calling that delay an isolated case. The pandemic offered an accidental glimpse of what earlier detection could change. Romania now needs a deliberate way to learn from every patient who follows.